EP1700947B1 - Fabric with active principles and relevant recharging method of the active principles - Google Patents
Fabric with active principles and relevant recharging method of the active principles Download PDFInfo
- Publication number
- EP1700947B1 EP1700947B1 EP06004931A EP06004931A EP1700947B1 EP 1700947 B1 EP1700947 B1 EP 1700947B1 EP 06004931 A EP06004931 A EP 06004931A EP 06004931 A EP06004931 A EP 06004931A EP 1700947 B1 EP1700947 B1 EP 1700947B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- fabric
- active principles
- hexapeptide
- anyone
- recharging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000004744 fabric Substances 0.000 title claims abstract description 54
- 238000000034 method Methods 0.000 title claims description 8
- 239000000126 substance Substances 0.000 claims abstract description 16
- 208000008960 Diabetic foot Diseases 0.000 claims abstract description 9
- 102000003886 Glycoproteins Human genes 0.000 claims abstract description 7
- 108090000288 Glycoproteins Proteins 0.000 claims abstract description 7
- 229920002334 Spandex Polymers 0.000 claims abstract description 3
- 239000003658 microfiber Substances 0.000 claims abstract description 3
- 239000004759 spandex Substances 0.000 claims abstract description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 13
- 239000003094 microcapsule Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000011505 plaster Substances 0.000 claims description 5
- 238000004804 winding Methods 0.000 claims description 5
- OFGVZFQUFJYSGS-CPDXTSBQSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s,3s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-3-methylbutanoic acid Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O OFGVZFQUFJYSGS-CPDXTSBQSA-N 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000002791 soaking Methods 0.000 claims description 2
- 241000519590 Pseudoalteromonas Species 0.000 claims 1
- 241000519593 Pseudoalteromonas antarctica Species 0.000 claims 1
- 238000003287 bathing Methods 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 229920001410 Microfiber Polymers 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 description 8
- 206010052428 Wound Diseases 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 230000007170 pathology Effects 0.000 description 7
- 239000013543 active substance Substances 0.000 description 6
- 230000036269 ulceration Effects 0.000 description 6
- 238000002266 amputation Methods 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 238000005299 abrasion Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000009958 sewing Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 208000012260 Accidental injury Diseases 0.000 description 1
- 241000590031 Alteromonas Species 0.000 description 1
- 231100000039 Ames test Toxicity 0.000 description 1
- 238000010953 Ames test Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000003643 Callosities Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 206010059516 Skin toxicity Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 210000000085 cashmere Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000024980 claudication Diseases 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 229920000912 exopolymer Polymers 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000011851 neurological alteration Diseases 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 231100000438 skin toxicity Toxicity 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Images
Classifications
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M15/00—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment
- D06M15/01—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment with natural macromolecular compounds or derivatives thereof
- D06M15/15—Proteins or derivatives thereof
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M23/00—Treatment of fibres, threads, yarns, fabrics or fibrous goods made from such materials, characterised by the process
- D06M23/12—Processes in which the treating agent is incorporated in microcapsules
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M2101/00—Chemical constitution of the fibres, threads, yarns, fabrics or fibrous goods made from such materials, to be treated
- D06M2101/16—Synthetic fibres, other than mineral fibres
- D06M2101/30—Synthetic polymers consisting of macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- D06M2101/38—Polyurethanes
Definitions
- the present invention refers to a fabric with active principles and to a recharging method of said principles having the main aim to prevent and/or to give the first cures to the diabetic foot.
- the problems to the feet caused to ulcers, accidental injuries, micro-traumas, wounds also light, callosity and infections.
- the persons with these pathologies have a reduced flux of blond in the inferior arts, in particular from the knee to the foot, owing to a stricture of the arteries.
- the diabetes gives a progressive destruction of the nerves that arrive to the foot and to a skin degeneration, that becomes dry and inflexible, so easy to be subjected to wounds.
- the concomitance of these events determines infections often careless and minimal realized to the diabetic patient, this due also to a minor sensibility of the nervous terminations of the foot.
- the degenerative forms created to a light wound are, owing to the complications given to the metabolic, circulatory and neurological alterations, not to disregard as they easily evolve in serious pathologies, unfortunately favourite to long times for healing the wounds in the diabetic patient, with consequent increasing of risk of bacterial, viral and mycotic infections.
- the complications of a normal disregarded ulceration are one of the more frequent causes of admission to hospital for this pathology.
- the non-prevention and non-care of that known as diabetic foot determines the claudication and, in the grave cases, the amputation of the art.
- a consistent percentage of diabetic persons are subjected to ulcerations to the feet that prolong in the time can grow worse.
- To have an idea of the problem are cited the data of the Health World Organization where are counted in one hundred and twenty million the diabetic persons in year 1996 and it is estimated in three hundred million the number of diabetic persons in year 2025, where on an average the 15% will have ulcerations to the feet with complications.
- Always from the cited sources are known data that counted that for one hundred diabetic patients with amputations eighty-four have had as cause of the amputation an ulceration to a foot grows worse in time.
- the invention creates a fabric, for specific application in this pathology, impregnated with substances with synergetic action and gradual release, and a recharging method of said active substances when these have lost their efficacy in time.
- the recharging of the active principles to the fabric permits a reusing of the specific fabric and it permits to have a set of clothes with controlled release of the active substances.
- the invention consists of a fabric 1 in lycra fibres and micro-fibres (known with the trade "meryl"), in variable percentages for application of this kind, that in actuation has the form of stocking 2, pantyhose 3, sock 4, winding bandage with closed border 5, bandage or plaster 6.
- This type of fabric has the characteristic to have fibres with minor or equal subtlety to ten micrometer. So the fibres of this fabric are of inferior diameter to that of the silk, that have a subtlety of the fibres of twelve micrometer of the cotton with subtlety of the fibres of thirteen and half micrometer of the cashmere with fibres diameter dimension of fifteen micrometer and of the wool with fibres diameter dimension of seventeen micrometer.
- the application of this characteristic of the invention is of big importance for the diabetic foot such as more the thread is thin minor are the damages to abrasion of the fabric onto the skin. So an extremely smooth fabric is obtained that no creates micro-abrasions onto the inelastic skin and dry of the diabetic patient.
- the fabric 1 is provided in the woof of thin silver yarns 7 with function anti-bacteric and bacteriostatic.
- pantyhose 3, sock 4 has a sewing with flat folding 8 in the anterior part of the stocking, imperceptible to the touch.
- the fabric 1 moreover, ha elastic property (elasticity of 99-100%) so to not obstruct the venous flux, to not worsening the occlusive peripheral arterypatia and to favourite the local microcirculation.
- it has capacity of umidity absorption, low rate of water retention and, differently to the natural fibres, quick time of drying.
- glycoprotein (9) (pseudoalteromonos ferment extract, known with the trade "antarcticine") synthesized to a bacteria (pseudoalteromanas antartica NF3) of the species Gram-negative, with composition of the fat acids and to the proteinic outline typical of the alteromonas family.
- This substance during the cellular growth produces a glycoprotein exopolymer composed of the 76-86% of proteins and to 8-14% of sugar, in base of the used means.
- This active substance have had use, previous to the invention, like a cosmetic humectant and emollient ingredient and like a substance with crioprotective property.
- Said active principle of new and original application in the treatment of the diabetic foot, has important property that opposed the dryness of the skin typical of the diabetic patient. It gives, infact, the coesion between the spinous and germinativum stratum favouring the madding and the folding of the interkeratociti liquids, so as estimated through the compression studies of the isotherms and of the multilayer of the Langmuir balance.
- said substance stimulates the growth of the human skin fibroblast in the tests in vitro without the growth of the keratinociti, so acting onto the micro-ulcerations of the skin to their first turning up and onto all the cute surface, from the knee to the foot.
- the active principle given to the cited substance increases the formation of elastin and of collagen type I and type IV with increasing of the cute hydration of at least the 45% in the twelve subsequent hours in comparison with a sample of skin not treated or treated with cream with the only placebo effect.
- This substance is inserted in the wet fabric in a quantity of at least 1 mg/ml.
- an exapeptide (10) from the alpha chain (known with trade "serilesine”).
- This peptide increases the adhesion of the cells, favours the cellular proliferation and betters the microcirculation such as it favours the angiogenesis.
- This active substance is added to the wet fabric 1 in quantity at least of 0,05 mg/ml. Also this last substance is never previous used for the use in pathology such that of the diabetic foot. Both these substances are previous used in the cosmetic field. So they do not present toxicity problems and they are not to be considered drugs to be prescribed with prescription.
- the fabric 1 is then washed in water at 50°C. Ending this working the water is discharged and the fabric is wet with clean water to which is added a mordanting assistant 12, the Nylofixam PM (sold by Clariant) that has the function to bound the substances contained in the microcapsules 11 to the aminic group of the fabric 1, by means of the polarization that favours the union between the fabric 1 and the substances 9 and 10 into the microcapsules.
- the fixer 12 is then added in proportion of 4% of the weight of the fabric 1 to treat. Then are introduced in the bath the microcapsules 11 in the dose previous described and in total quantity of the 6% of the weight of the fabric. After ten minutes is added a cationic product 13, i.e.
- softenol 70 (sold by Lautex) that contributes also it to bound the microcapsules 11 with the fabric 1.
- the "lautex” is added in percentage of 2% of the weight of the fabric. After ninety minutes the bath is let out and the fabric 1 is centrifuged and dry, ready to be used.
- the microcapsules 11 and the fixers 12 and 13 to the fabric 1 are sold in pre-dosed packaging, to can use the stocking 2, the pantyhose 3, the sock 4, the winding bandage 5, the bandage or plaster 6.
- To actuate the recharging of the active substances 9 and 10 to the fabric 1 for domestic three grams of substances 9 and 10 in microcapsules 11 are brought and they are dissolved into 300-500 ml.
- the simple application of a cream with active principles does not reach the useful results for the diabetic foot pathology such as the results obtained with the invention such as the friction of the foot with the conventional pantyhose creates, during the walk, frictions that take off the cream instead of makes it to absorb to the skin of the foot and neither the occlusive bandages with cream and gauzes are not to be used if no with the patient in bed.
- the invention is so to be used in the daily without constraints and/or changing to the style of life of the patient.
- the invention in the application in the form of application also winding bandage 5, cicatrizant bandage or plaster 6 have application also remedy for the bedsores and/or light wounds..
- FIG. 1 is view of an example of production like a stocking.
- Figure 2 is view of an application like a stock.
- Figure 3 is view of the version like a pantyhose.
- Figure 4 is view of the version of winding bandage with closed profile.
- Figure 5 is view of the version of bandage or plaster.
- sheet 2 are illustrated some sequences of the recharging phase of the active principles of the invention.
- figure 6 is view of the immersion phase.
- Figure 7 is view of the invention soaks in water with the active principles.
Landscapes
- Engineering & Computer Science (AREA)
- Textile Engineering (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Detergent Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
- The present invention refers to a fabric with active principles and to a recharging method of said principles having the main aim to prevent and/or to give the first cures to the diabetic foot. Between the diabetes complications are known the problems to the feet caused to ulcers, accidental injuries, micro-traumas, wounds also light, callosity and infections. Are known the grave damages and the risks of grafting of important complications from light wounds in the diabetic patient. The persons with these pathologies have a reduced flux of blond in the inferior arts, in particular from the knee to the foot, owing to a stricture of the arteries. Moreover, the diabetes gives a progressive destruction of the nerves that arrive to the foot and to a skin degeneration, that becomes dry and inflexible, so easy to be subjected to wounds. The concomitance of these events determines infections often careless and minimal realized to the diabetic patient, this due also to a minor sensibility of the nervous terminations of the foot. The degenerative forms created to a light wound are, owing to the complications given to the metabolic, circulatory and neurological alterations, not to disregard as they easily evolve in serious pathologies, unfortunately favourite to long times for healing the wounds in the diabetic patient, with consequent increasing of risk of bacterial, viral and mycotic infections. The complications of a normal disregarded ulceration are one of the more frequent causes of admission to hospital for this pathology. The non-prevention and non-care of that known as diabetic foot determines the claudication and, in the grave cases, the amputation of the art. A consistent percentage of diabetic persons are subjected to ulcerations to the feet that prolong in the time can grow worse. To have an idea of the problem are cited the data of the Health World Organization where are counted in one hundred and twenty million the diabetic persons in year 1996 and it is estimated in three hundred million the number of diabetic persons in year 2025, where on an average the 15% will have ulcerations to the feet with complications. Always from the cited sources are known data that counted that for one hundred diabetic patients with amputations eighty-four have had as cause of the amputation an ulceration to a foot grows worse in time. Moreover, over the 50% of all the amputations of the lower limbs regards diabetic patients. Currently are not known local preventive applications to be constantly used to prevent, cure or reinforce the defences of the foot of the diabetic patient so to avoid the complications previous described. The sole forms of prevention in this delicate sector are given prevalently based onto mode of behaviour as the careful test of the food, the sanitary education for observation of hygienic rules, the using of correct shoes and the application of topical remedy at the appearing of the first ulcerations. The invention, instead, realizes a therapeutic remedy able to prevent the formation of ulcerations and to favourite the recovery of wounds eventually formed. The invention creates a fabric, for specific application in this pathology, impregnated with substances with synergetic action and gradual release, and a recharging method of said active substances when these have lost their efficacy in time. The recharging of the active principles to the fabric permits a reusing of the specific fabric and it permits to have a set of clothes with controlled release of the active substances. The invention consists of a
fabric 1 in lycra fibres and micro-fibres (known with the trade "meryl"), in variable percentages for application of this kind, that in actuation has the form of stocking 2,pantyhose 3,sock 4, winding bandage withclosed border 5, bandage orplaster 6. This type of fabric, with new application for the specific pathology of the diabetic foot, has the characteristic to have fibres with minor or equal subtlety to ten micrometer. So the fibres of this fabric are of inferior diameter to that of the silk, that have a subtlety of the fibres of twelve micrometer of the cotton with subtlety of the fibres of thirteen and half micrometer of the cashmere with fibres diameter dimension of fifteen micrometer and of the wool with fibres diameter dimension of seventeen micrometer. The application of this characteristic of the invention is of big importance for the diabetic foot such as more the thread is thin minor are the damages to abrasion of the fabric onto the skin. So an extremely smooth fabric is obtained that no creates micro-abrasions onto the inelastic skin and dry of the diabetic patient. In other embodiment of the invention thefabric 1 is provided in the woof ofthin silver yarns 7 with function anti-bacteric and bacteriostatic. To avoid grazes from sewing the invention, in the form of the stocking 2,pantyhose 3,sock 4, has a sewing withflat folding 8 in the anterior part of the stocking, imperceptible to the touch. Thefabric 1, moreover, ha elastic property (elasticity of 99-100%) so to not obstruct the venous flux, to not worsening the occlusive peripheral arterypatia and to favourite the local microcirculation. Unlike to the other synthetic fibres, moreover, it has capacity of umidity absorption, low rate of water retention and, differently to the natural fibres, quick time of drying. These characteristic have like resulting capacity to oppose the formation of fungus and to limit the bacteric growth. To thefabric 1 are then added active substances with application method to the fabric and recharging method of new conception. To thefabric 1 is bound a glycoprotein (9) (pseudoalteromonos ferment extract, known with the trade "antarcticine") synthesized to a bacteria (pseudoalteromanas antartica NF3) of the species Gram-negative, with composition of the fat acids and to the proteinic outline typical of the alteromonas family. This substance during the cellular growth produces a glycoprotein exopolymer composed of the 76-86% of proteins and to 8-14% of sugar, in base of the used means. This active substance have had use, previous to the invention, like a cosmetic humectant and emollient ingredient and like a substance with crioprotective property. Said active principle, of new and original application in the treatment of the diabetic foot, has important property that opposed the dryness of the skin typical of the diabetic patient. It gives, infact, the coesion between the spinous and germinativum stratum favouring the madding and the folding of the interkeratociti liquids, so as estimated through the compression studies of the isotherms and of the multilayer of the Langmuir balance. Moreover, said substance stimulates the growth of the human skin fibroblast in the tests in vitro without the growth of the keratinociti, so acting onto the micro-ulcerations of the skin to their first turning up and onto all the cute surface, from the knee to the foot. Moreover, the active principle given to the cited substance increases the formation of elastin and of collagen type I and type IV with increasing of the cute hydration of at least the 45% in the twelve subsequent hours in comparison with a sample of skin not treated or treated with cream with the only placebo effect. This substance is inserted in the wet fabric in a quantity of at least 1 mg/ml. To thefabric 1 is then added, without order of insertion to the fabric but with modality of charge and recharge following described, an exapeptide (10) from the alpha chain (known with trade "serilesine"). This peptide increases the adhesion of the cells, favours the cellular proliferation and betters the microcirculation such as it favours the angiogenesis. This active substance is added to thewet fabric 1 in quantity at least of 0,05 mg/ml. Also this last substance is never previous used for the use in pathology such that of the diabetic foot. Both these substances are previous used in the cosmetic field. So they do not present toxicity problems and they are not to be considered drugs to be prescribed with prescription. In particular they do not have, such the made tests has certified, cytotoxicity on human fibroblasts, cytotoxicity on keratinocity, they have no given toxicity prove in the tests of hemolysis, in the tests of genotoxicity, i.e. in the Ames tests, and they are not irritating as valuing with the het-cam for the valuation of the potential ocular irritation. The used substances in the described concentrations do not create irritation to the skin, sensitization phenomenon, ocular irritation and oral and skin toxicity. Thesesubstances fabric 1 essentially for coulomb bond, being they with prevalent positive charge whereas the fabric has fibres with negative charge for own constitution. Thesubstances microcapsules 11 soluble in water. Thefabric 1 is then washed in water at 50°C. Ending this working the water is discharged and the fabric is wet with clean water to which is added amordanting assistant 12, the Nylofixam PM (sold by Clariant) that has the function to bound the substances contained in themicrocapsules 11 to the aminic group of thefabric 1, by means of the polarization that favours the union between thefabric 1 and thesubstances fixer 12 is then added in proportion of 4% of the weight of thefabric 1 to treat. Then are introduced in the bath themicrocapsules 11 in the dose previous described and in total quantity of the 6% of the weight of the fabric. After ten minutes is added acationic product 13, i.e. softenol 70 (sold by Lautex) that contributes also it to bound themicrocapsules 11 with thefabric 1. The "lautex" is added in percentage of 2% of the weight of the fabric. After ninety minutes the bath is let out and thefabric 1 is centrifuged and dry, ready to be used. In the version for the domestic use themicrocapsules 11 and thefixers fabric 1 are sold in pre-dosed packaging, to can use the stocking 2, thepantyhose 3, thesock 4, thewinding bandage 5, the bandage orplaster 6. To actuate the recharging of theactive substances fabric 1 for domestic three grams ofsubstances microcapsules 11 are brought and they are dissolved into 300-500 ml. of water, after to have washed the usedfabric 1, at a temperature inferior to 40°C. The pantyhose, or the sock or the other forms of thefabric 1 are then left in soaking for 15-20 minutes. These products are then dry in air. After this treatment thefabric 1 have an uniform distribution of the active principles. With pre-determined times are provided rechargings, also conserving the active principles effectiveness till the third days of use. The invented product conserves the active principles also after three washings. However, it is suggested the daily washing and the recharging after three days from the first use with the method above described. The simple application of a cream with active principles does not reach the useful results for the diabetic foot pathology such as the results obtained with the invention such as the friction of the foot with the conventional pantyhose creates, during the walk, frictions that take off the cream instead of makes it to absorb to the skin of the foot and neither the occlusive bandages with cream and gauzes are not to be used if no with the patient in bed. The invention is so to be used in the daily without constraints and/or changing to the style of life of the patient. The invention in the application in the form of application also windingbandage 5, cicatrizant bandage orplaster 6 have application also remedy for the bedsores and/or light wounds.. The cicatrizant action, the better of the micro-circulation and the effect on the derma determine a quick healing of these woods without collateral effects. The invention is illustrated in a merely indicative way in the drawings ofsheets 1 and 2. Insheet 1figure 1 is view of an example of production like a stocking. In the same table 1 thefigure 2 is view of an application like a stock.Figure 3 is view of the version like a pantyhose.Figure 4 is view of the version of winding bandage with closed profile.Figure 5 is view of the version of bandage or plaster. In sheet 2 are illustrated some sequences of the recharging phase of the active principles of the invention. In detailfigure 6 is view of the immersion phase.Figure 7 is view of the invention soaks in water with the active principles.
Claims (7)
- A fabric with active principles (1), said fabric consisting of lycra fibres and micro-fibres, characterized in that it has distributed along the fibres, as active principles, a glycoprotein (9) and a hexapeptide (10), wherein said active principles prevent and/or give the first cures to the diabetic foot.
- The fabric according to claim 1, in which said glycoprotein (9) is the Pseudoalteromonas ferment extract, synthesized by the bacteria Pseudoalteromonas Antarctica NF3, and said hexapeptide (10) is the hexapeptide from the alpha chain serilesine.
- The fabric according to anyone of claims 1-2, in which said active principles, glycoprotein (9) and hexapeptide (10), are mixed into microcapsules (11) soluble in water.
- The fabric according to anyone of the preceding claims, in which said active principles, glycoprotein (9) and hexapeptide (10), are bound to the fabric essentially for coulomb bonds.
- The fabric according to anyone of the preceding claims, said fabric having the production form of a stocking (2), of a pantyhose (3), of a sock (4), of a winding bandage with closer border (5) of a bandage or plaster (6) to realize a continuous and persistent contact with the skin of the diabetic patient.
- A method for recharging the active principles into a fabric according to anyone of claims 1-5, characterized in that the recharging or the first charging of the washed fabric is actuated bathing the fabric (1) with clean water to which is added a fixer, Nylofixan PM (12), in proportion of 4% of the weight of the fabric (1) to be treated, subsequently putting in the bath the microcapsules (11), containing the active principles (9) and (10), in a total quantity equal to 6% of the weight of the fabric, then, after ten minutes, a the cationic product Softenol 70 is added in percentage of 2% of the weight of the fabric and, after ninety minutes, the bath is discharged and the fabric (1) is centrifuged and dried.
- A method for recharging the active principles into a fabric according to anyone of claims 1-5, characterized in that it provides, for the recharging in domestic use, the use of three grams of the substances (9) and (10) into the microcapsules (11), dissolved into 300-500 ml of water at a temperature inferior to 40°C, and subsequent soaking of the fabric (1) for at least fifteen minutes.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE602006008679T DE602006008679D1 (en) | 2005-03-11 | 2006-03-10 | Tissue-loaded tissue, as well as the corresponding procedure for recharging the active ingredients |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000140A ITBO20050140A1 (en) | 2005-03-11 | 2005-03-11 | FABRIC WITH ACTIVE PRINCIPLES AND RELATED METHOD OF RECHARGING ACTIVE INGREDIENTS |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1700947A2 EP1700947A2 (en) | 2006-09-13 |
EP1700947A3 EP1700947A3 (en) | 2007-07-18 |
EP1700947B1 true EP1700947B1 (en) | 2009-08-26 |
Family
ID=36581655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06004931A Active EP1700947B1 (en) | 2005-03-11 | 2006-03-10 | Fabric with active principles and relevant recharging method of the active principles |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1700947B1 (en) |
AT (1) | ATE440994T1 (en) |
DE (1) | DE602006008679D1 (en) |
ES (1) | ES2332374T3 (en) |
IT (1) | ITBO20050140A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10149799B2 (en) | 2010-03-25 | 2018-12-11 | Sigvaris Ag | Compression textiles |
AU2015340458B2 (en) * | 2014-10-31 | 2021-07-08 | Lipotec, S.A.U. | Cosmetic and/or pharmaceutical composition containing a bacterial extracellular product from pseudoalteromonas antarctica, and use thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2336995B1 (en) * | 2008-10-13 | 2011-02-09 | Lipotec, S.A. | COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION FOR SKIN CARE, HAIR LEATHER AND NAILS. |
EP2540263A1 (en) | 2011-06-29 | 2013-01-02 | Sigvaris Inc. | Graduated compression garments |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1638494B1 (en) * | 2003-07-02 | 2014-05-07 | Invista Technologies S.à.r.l. | Sleeve-like knitted structure for use as a castliner |
-
2005
- 2005-03-11 IT IT000140A patent/ITBO20050140A1/en unknown
-
2006
- 2006-03-10 AT AT06004931T patent/ATE440994T1/en active
- 2006-03-10 ES ES06004931T patent/ES2332374T3/en active Active
- 2006-03-10 EP EP06004931A patent/EP1700947B1/en active Active
- 2006-03-10 DE DE602006008679T patent/DE602006008679D1/en active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10149799B2 (en) | 2010-03-25 | 2018-12-11 | Sigvaris Ag | Compression textiles |
AU2015340458B2 (en) * | 2014-10-31 | 2021-07-08 | Lipotec, S.A.U. | Cosmetic and/or pharmaceutical composition containing a bacterial extracellular product from pseudoalteromonas antarctica, and use thereof |
Also Published As
Publication number | Publication date |
---|---|
DE602006008679D1 (en) | 2009-10-08 |
ATE440994T1 (en) | 2009-09-15 |
EP1700947A3 (en) | 2007-07-18 |
ES2332374T3 (en) | 2010-02-03 |
ITBO20050140A1 (en) | 2006-09-12 |
EP1700947A2 (en) | 2006-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9220636B2 (en) | Sock for treatment of foot and leg wounds, methods of use and manufacture | |
US10149799B2 (en) | Compression textiles | |
US20140221948A1 (en) | Hygienic or personal care article having a content of copper or copper ions | |
US10639469B2 (en) | Sock for treatment of foot and leg wounds, methods of use and manufacture | |
JP2009523474A (en) | Antiseptic alginate preparation | |
Haug et al. | Coated textiles in the treatment of atopic dermatitis | |
EP1700947B1 (en) | Fabric with active principles and relevant recharging method of the active principles | |
CN202932044U (en) | Antibacterial deodorant stocking | |
Vachhrajani et al. | Science of wound healing and dressing materials | |
US20090280151A1 (en) | Fabric with active principles and relevant recharging method of the active principles | |
US7166307B1 (en) | Herb medicine composition to be spread on sanitary napkin for female | |
CA2627223A1 (en) | Wound-healing pharmaceutical compositions in the form of a sterile powder based on amino acids and sodium hyaluronate | |
WO2020144564A1 (en) | Composition for the treatment of skin lesions and irritations | |
CN101003943A (en) | Nano antibacterial cotton textile materials, and a series of commodity of sanitation | |
JPH1037070A (en) | Antimicrobial fiber containing catechin of green tea component | |
KR101821965B1 (en) | Functional stocking socks having an double fabric structure | |
CN103147271A (en) | Nano antibiosis and bacteriostasis cotton textile material and products thereof | |
Heide et al. | Antimicrobial-finished textile three-dimensional structures | |
CN1874748A (en) | Textile and footwear products treated with sulfur | |
Shirvan et al. | Allergies caused by textiles and their control | |
Bairagi et al. | Textile structures for medical applications | |
EP2667904B1 (en) | Compression stockings and tubes with bioactive agents for the treatment of venous insufficiency and varicose veins | |
KR200367929Y1 (en) | Nano silver socks | |
Marinova | THE EFFECT OF TOPICAL APPLICATION WITH OZOILE® AS A NOVEL METHOD IN THE COMPLEX TREATMENT OF SOFT TISSUE INFECTIONS AND CHRONIC WOUNDS. | |
CN101108209A (en) | Traditional Chinese medicine for treating beriberi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK YU |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK YU |
|
17P | Request for examination filed |
Effective date: 20080116 |
|
17Q | First examination report despatched |
Effective date: 20080226 |
|
AKX | Designation fees paid |
Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 602006008679 Country of ref document: DE Date of ref document: 20091008 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: BUGNION S.A. |
|
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20090826 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090826 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091226 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090826 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090826 |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2332374 Country of ref document: ES Kind code of ref document: T3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090826 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090826 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090826 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090826 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091126 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090826 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090826 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090826 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090826 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090826 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090826 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090826 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20100527 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100331 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091127 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100310 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100310 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100227 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090826 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20170222 Year of fee payment: 12 Ref country code: CH Payment date: 20170227 Year of fee payment: 12 Ref country code: FR Payment date: 20170221 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20170224 Year of fee payment: 12 Ref country code: AT Payment date: 20170222 Year of fee payment: 12 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: ING. MARCO ZARDI C/O M. ZARDI AND CO. S.A., CH Ref country code: CH Ref legal event code: PUE Owner name: HARMONIUM INVESTMENTS LIMITED, GB Free format text: FORMER OWNER: LVM TECHNOLOGIES S.R.L., IT Ref country code: CH Ref legal event code: PUE Owner name: LVM TECHNOLOGIES S.R.L., IT Free format text: FORMER OWNER: RESTANI, MORENA, IT |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602006008679 Country of ref document: DE Representative=s name: MOSER GOETZE & PARTNER PATENTANWAELTE MBB, DE Ref country code: DE Ref legal event code: R081 Ref document number: 602006008679 Country of ref document: DE Owner name: HARMONIUM INVESTMENTS LTD., GB Free format text: FORMER OWNERS: RESTANI, MORENA, CALDERATA DI RENO, IT; LENZI, LUCIO, VERGATO, IT |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20170921 AND 20170927 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20170928 AND 20171004 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: PC2A Owner name: LVM TECHNOLOGIES S.R.L. Effective date: 20171113 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: PC2A Owner name: HARMONIUM INVESTMENTS LIMITED Effective date: 20171205 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: TP Owner name: HARMONIUM INVESTMENTS LIMITED, GB Effective date: 20171213 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602006008679 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 440994 Country of ref document: AT Kind code of ref document: T Effective date: 20180310 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20180310 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181002 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180310 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180331 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180331 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180310 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180331 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20190904 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180311 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20240325 Year of fee payment: 19 |